About BioMimetic Therapeutics (NASDAQ:BMTI)
BioMimetic Therapeutics, Inc. is a biotechnology company engaged in developing and commercializing products to the healing of musculoskeletal injuries and diseases, including therapies for orthopedic, sports medicine and spine applications. The Company's Augment platform of product and product candidates include an engineered version of recombinant human platelet-derived growth factor BB (rhPDGF-BB), one of the wound healing and tissue repair stimulators in the body. Its platform regenerative technology for promoting tissue healing and regeneration combines rhPDGF-BB with tissue specific matrices, when appropriate. The matrices are engineered or natural scaffold materials, such as Beta Tri-Calcium Phosphate. The Company's product candidates include Augment Bone Graft (Augment), Augmen Injectable Bone Graft (Augment Injectable) and Augment Rotator Cuff Graft (Augment Rotator Cuff Graft). In March 2013, Wright Medical Group Inc completed acquisition of BioMimetic Therapeutics, Inc.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on AssetsN/A
BioMimetic Therapeutics (NASDAQ:BMTI) Frequently Asked Questions
What is BioMimetic Therapeutics' stock symbol?
BioMimetic Therapeutics trades on the NASDAQ under the ticker symbol "BMTI."
Who are some of BioMimetic Therapeutics' key competitors?
Some companies that are related to BioMimetic Therapeutics include Johnson & Johnson (JNJ), Novartis (NVS), UnitedHealth Group (UNH), Pfizer (PFE), AbbVie (ABBV), Roche (ROG), Amgen (AMGN), Bristol-Myers Squibb (BMY), Abbott Laboratories (ABT), Gilead Sciences (GILD), Novo Nordisk A/S (NVO), Sanofi (SNY), GlaxoSmithKline (GSK), Eli Lilly and (LLY), Thermo Fisher Scientific (TMO), AstraZeneca (AZN), Bayer (BAYN) and Sanofi (SAN).
How do I buy BioMimetic Therapeutics stock?
Shares of BioMimetic Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact BioMimetic Therapeutics?
BioMimetic Therapeutics' mailing address is 389 Nichol Mill Lane, FRANKLIN, TN 37067, United States. The biotechnology company can be reached via phone at +1-615-8441280.
MarketBeat Community Rating for BioMimetic Therapeutics (BMTI)MarketBeat's community ratings are surveys of what our community members think about BioMimetic Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
BioMimetic Therapeutics (NASDAQ:BMTI) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
BioMimetic Therapeutics (NASDAQ:BMTI) Earnings History and Estimates Chart
BioMimetic Therapeutics (NASDAQ BMTI) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
BioMimetic Therapeutics (NASDAQ:BMTI) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for BioMimetic Therapeutics (NASDAQ:BMTI)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for BioMimetic Therapeutics (NASDAQ BMTI)
No insider trades for this company have been tracked by MarketBeat.com
BioMimetic Therapeutics (NASDAQ BMTI) News Headlines
No headlines for this company have been tracked by MarketBeat.com
BioMimetic Therapeutics (NASDAQ:BMTI) SEC Filings
This page is loading this company's SEC Filings. Please wait...
BioMimetic Therapeutics (NASDAQ:BMTI) Income Statement, Balance Sheet and Cash Flow Statement
BioMimetic Therapeutics (NASDAQ BMTI) Stock Chart for Saturday, February, 17, 2018